STVN earnings

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter 2026 on Thursday, May 7, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Thursday, May 7, 2026, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-registrat

- Establishes Fiscal 2026 Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2025. Fourth Quarter and Full Year 2025 Highlights (comparisons to prior-year periods) For the fourth quarter of 2025, revenue increased 5% (7% on a constant currency basis) to €346.5 million, and high-value solutions represented 49% of total revenue. Gross profit margin increased 120 basis points to 30.9%, and adjusted EBITDA margin increased 70 basis points to 28.2%, for the fourth

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 4, 2026, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Wednesday, March 4, 2026, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its web

Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr

Company delivers 8% revenue growth, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0 million, and high-value solutions represented 42% of total revenue. Gross profit margin increased 210 basis points to 28.1%. Diluted earnings per share were €0.11; adjusted diluted earnings per share were €0.11. Adjusted EBITDA mar

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2025 on Tuesday, August 5, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, August 5, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-reg

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2025. First Quarter 2025 Highlights (comparisons to prior-year period) Revenue for the first quarter of 2025 increased 9% to €256.6 million, and high-value solutions represented 43% of total revenue. Gross profit margin increased 80 basis points to 27.2%. Diluted earnings per share were €0.10, and adjusted diluted earnings per share were €0.10. Adjusted EBITDA margin increased 100 basis points to 22.4%. The Company is maintaining

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2025 on Thursday, May 8, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 8, 2025, to discuss financial results. During the call, management will refer to a slide presentation, which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-registrat

- Introduces 2025 Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and fiscal year 2024. Fourth Quarter and Full-Year 2024 Highlights (comparisons to prior-year period) Revenue for the fourth quarter of 2024 increased 3% to €330.6 million, and high-value solutions represented 40% of total revenue, in line with Company expectations. For the fourth quarter, diluted earnings per share were €0.18, and adjusted diluted earnings per share were €0.19. Adjusted EBITDA margin incre

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2024 on Thursday, March 6, 2025, at 6:30 a.m.(ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation that will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website.

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2024. Third Quarter 2024 Highlights Revenue for the third quarter of 2024 increased 2% to €277.9 million, compared with the same period last year, and high-value solutions represented 36% of total revenue. For the third quarter, diluted earnings per share were €0.11 and adjusted diluted earnings per share were €0.12. Adjusted EBITDA margin for the third quarter was 22.9%. The Company is maintaining its fiscal year 2024 revenue guida

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the third quarter of 2024 on Tuesday, November 5, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 5, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-regi

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2024. Second Quarter 2024 Highlights Revenue for the second quarter of 2024 increased 2% to €259.6 million, compared with the same period last year, and high-value solutions represented 40% of total revenue. For the second quarter, diluted earnings per share were €0.08 and adjusted diluted earnings per share were €0.09. Adjusted EBITDA margin for the second quarter was 20.8%. The Company is updating its fiscal year 2024 guidan

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, announced today that it will issue financial results for the second quarter of 2024 on Tuesday, August 6, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, August 6, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-regis

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2024 on Thursday, May 9, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 9, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-registra

- Establishes 2024 Guidance- Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2023. Fourth Quarter and FY 2023 Highlights (compared with the same period last year) Revenue for the fourth quarter of 2023 increased 10% to €320.6 million, and high-value solutions represented 37% of total revenue. For the fourth quarter, diluted earnings per share were €0.17 and adjusted diluted earnings per share were €0.18. Adjusted EBITDA margin for the fourth quarter was 27%. F

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and year end of 2023 on Thursday, March 7, 2024, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 7, 2024, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its websi

- Reiterates Full Year 2023 Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2023. Third Quarter 2023 Highlights (compared with the same period last year) Third quarter revenue increased 11% to €271.4 million. Revenue from high-value solutions increased to 32% of total revenue. Net profit increased 4% to €37.9 million, and diluted earnings per share were €0.14. Adjusted net profit increased 6% to €40.1 million, and adjusted diluted earnings per share were €0.15.

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2023 on Tuesday, October 31, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, October 31, 2023 to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-r

- Reiterates Full Year 2023 Revenue and Adjusted Diluted Earnings per Share Guidance; Increases Adjusted EBITDA Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2023. Second Quarter 2023 Highlights (compared with the same period last year) Second quarter revenue increased 9% to €255.3 million. Revenue from high-value solutions increased to 33% of total revenue. Diluted earnings per share were €0.13; adjusted diluted earnings per share were €0.14. Adjusted EBITDA

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2023 on Friday, July 28, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Friday, July 28, 2023 to discuss financial results. During the call, management will refer to a slide presentation which will be available at 6:30 a.m. (ET) on the day of the call on the "Financial Results" page under the Company's Investor Relations section of its website.

- Reiterates Full Year 2023 Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2023, and maintained its fiscal 2023 guidance. First Quarter 2023 Highlights (compared with the same period last year) First quarter revenue increased 12% to €238 million. Revenue from high value solutions increased to 32% of total revenue. Diluted earnings per share of €0.11 and adjusted diluted earnings per share of €0.11. Adjusted EBITDA margin increased 50 basis points to 26%. The

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the first quarter of 2023 on Thursday, May 4, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, May 4, 2023 to discuss financial results. During the call, management will refer to a slide presentation which will be available at 6:30 a.m. (ET) on the day of the call on the "Financial Results" page under the Company's Investor Relations section of its website.

- Establishes Fiscal 2023 Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2022, and established fiscal 2023 guidance. Fourth Quarter and Full Year 2022 Highlights (compared with the same periods last year) Fourth quarter revenue increased 26% to €292.1 million, diluted EPS were €0.18, and adjusted diluted EPS were €0.19. Adjusted EBITDA margin was 28%. Fiscal year 2022 revenue grew 17% to €983.7 million, diluted EPS were €0.54, and adjusted diluted EPS were €0

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2022 on Thursday, March 2, 2023, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, March 2, 2023 to discuss financial results. During the call, management will refer to a slide presentation which will be available at 6:30 a.m. (ET) on the day of the call on the "Financial Results" page under the Company's Investor Relations section

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2022. Third Quarter 2022 Highlights Third quarter revenue increased 14% to €245.3 million, over the same period last year Revenue from high value solutions was approximately 30% of total revenue Reported diluted earnings per share of €0.14 and adjusted diluted earnings per share of €0.14 Adjusted EBITDA totaled €65.8 million with an adjusted EBITDA margin of 26.8% Committed backlog increased 21% to approximately €1.01 billion, ove

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2022 on Tuesday, November 8, 2022, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Tuesday, November 8, 2022 to discuss financial results for the third quarter. During the call, management will refer to a slide presentation which will be available at 6:30 a.m. (ET) on the day of the call on the "Financial Results" page under the Company's Investor Relati

- Raises Fiscal 2022 Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2022. Second Quarter 2022 Highlights (compared to the same period last year) Second quarter revenue increased 15% to €234.2 million, Diluted earnings per share of €0.12 and adjusted diluted earnings per share of €0.12, Adjusted EBITDA totaled €61.8 million with an adjusted EBITDA margin of 26.4%, Backlog increased 37% to approximately €1.01 billion, Revenue from high value solutions increased to a

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2022 on Thursday, August 4, 2022, at 6:30 a.m. (EST). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EST) on Thursday, August 4, 2022 to discuss results. Management will refer to a slide presentation which will be available at 6:30 a.m. (EST) on the day of the call on the "Financial Results" page of the Company's Investor Relations section of its website. Pre-registration: Par

- The Company is Maintaining its Fiscal 2022 Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the first quarter of 2022. First Quarter 2022 Highlights (compared to the same period last year) First quarter revenue increased 10% to €212.1 million, diluted earnings per share were €0.10 and adjusted diluted earnings per share were €0.11, Adjusted EBITDA totaled €54.0 million with an adjusted EBITDA margin of 25.5%, Backlog increased 49% to approximately €992.2 million, Revenue from high value

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the first quarter of 2022 on Tuesday, May 10, 2022, at 6:30 a.m. Eastern Time (12:30 Central European Time). The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 Central European Time) on Tuesday, May 10, 2022. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the slide presentation, please visit the "Financial Results" p

- Establishes Full Year 2022 Guidance - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter 2021. Fourth Quarter and Full Year Highlights (compared to the same period last year) Fourth quarter revenue increased 12.5% to €232.6 million, diluted EPS were €0.17 and adjusted diluted EPS were €0.13. Adjusted EBITDA margin was 25.3%, Full year revenue grew 27.5% to €843.9 million, diluted EPS were €0.53 and adjusted diluted EPS were €0.48. Adjusted EBITDA margin increased to 25.9%, Backlog in

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the fourth quarter and full year of fiscal year 2021 on Tuesday, March 8, 2022, at 6:30 a.m. Eastern Time (12:30 Central European Time). The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 Central European Time) on Tuesday, March 8, 2022. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the slide presentation, please vi

Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the third quarter of fiscal 2021 on Tuesday, November 9, 2021 at 6:30 a.m. Eastern Time (12:30 CET). The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 CET) on November 9, 2021. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, please visit the "Financial Results" page, under the Financial Information

Stevanato Group S.p.A. (NYSE:STVN) a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will issue financial results for the second quarter of fiscal year 2021 on Thursday, August 19, 2021. The Company will host a conference call to discuss the financial results at 8:30 a.m. Eastern Time (14:30 CET) on August 19, 2021. Management will refer to a slide presentation during the call, which will be made available on the day of the call. To view the presentation, please visit the "Financial Results" page, under the Company's Investor Relations section of its website. To